Main menu

Recent Pfizer Press Releases

2/21/14 11:06am EST
In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation[i]

Data from Phase 3 ARISTOTLE trial pre-specified subanalysis published in the European Heart Journal 

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). This subanalysis found consistent results across age groups for reducing the risk of stroke and systemic embolism and reducing the risk of all-cause death with fewer bleeding events. Owing to the higher risk at older age (age 75 and older), the absolute benefit to patients with NVAF was greater with Eliquis in the older population. These data were published today in the European Heart Journal.

more...
2/11/14 2:04pm EDT
Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees

Pfizer agrees with the recommendation of the joint meeting of the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee that the available data do not support a conclusion that naproxen has a lower risk of cardiovascular thrombotic events as compared to other non-steroidal anti-inflammatory drugs (NSAIDs). 

more...
2/5/14 6:45am EST
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

Agreement to Combine Merck’s Investigational Anti-PD-1 and Key Pfizer Oncology Assets 

Pfizer Inc. (NYSE:PFE) announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada (“Merck”), through two Merck subsidiaries, to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.  A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s axitinib (INLYTA®) in renal cell carcinoma (RCC).  A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566), Pfizer’s investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation and survival. 

more...
2/3/14 7:00am EST
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer

Clinical Benefit Demonstrated For Potential First-in-Class CDK 4 and 6 Inhibitor

Pfizer Inc. (NYSE: PFE) today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.  

more...
1/28/14 7:00am EST
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis(3) on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012. Results and guidance are summarized below.

more...
1/27/14 7:00am EST
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer

An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC   

Pfizer Inc. (NYSE:PFE) today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer (NSCLC).

more...
1/23/14 8:00am EST
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.  In this study, ALO-02 met the primary efficacy endpoint, demonstrating a statistically significant difference from placebo.

more...
1/22/14 10:00am EST
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating

Match.com and Pfizer (NYSE: PFE) today announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year.  Nearly 9 out of 10 (89 percent) respondents said they prefer not to date someone who smokes, and when asked which actions were unacceptable on a first date, more said taking a smoke break (51 percent) than checking one’s phone (45 percent) or being late (40 percent). 

Match.com and Pfizer (NYSE: PFE) today announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year.  Nearly 9 out of 10 (89 percent) respondents said they prefer not to date someone who smokes, and when asked which actions were unacceptable on a first date, more said taking a smoke break (51 percent) than checking one’s phone (45 percent) or being late (40 percent). 
 
more...
1/17/14 10:15am EST
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health

Freda Lewis-Hall, M.D., Pfizer’s executive vice president and chief medical officer, today issued a statement regarding the 50th Anniversary of the First Surgeon General's Report on Smoking and Health.

more...

Pages